# A Mobile App-Based Study to Evaluate Disease Burden and Treatment Patterns in Immunoglobulin A Nephropathy (IgAN) in the US

> **NCT06952426** · — · RECRUITING · sponsor: **Novartis Pharmaceuticals** · enrollment: 300 (estimated)

## Conditions studied

- Immunoglobulin A Nephropathy

## Interventions

- **OTHER:** No intervention
- **OTHER:** Other treatment
- **OTHER:** Iptacopan
- **OTHER:** Atrasentan

## Key facts

- **NCT ID:** NCT06952426
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2025-03-04
- **Primary completion:** 2025-06-30
- **Final completion:** 2025-06-30
- **Target enrollment:** 300 (ESTIMATED)
- **Last updated:** 2025-06-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06952426

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06952426, "A Mobile App-Based Study to Evaluate Disease Burden and Treatment Patterns in Immunoglobulin A Nephropathy (IgAN) in the US". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06952426. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*